Apellis Pharmaceuticals, Inc. — Director's Dealing 2017

Nov 13, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2017-11-13

Reporting Person: venBio Global Strategic Fund II L.P. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-11-13	Common Stock	C	3451790	—	Acquired	3451790	Direct
2017-11-13	Common Stock	P	127515	$14.00	Acquired	3579305	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-11-13	Series D Preferred Stock	$	C	6714413	Disposed		Common Stock (3147872)	Direct
2017-11-13	Series E Preferred Stock	$	C	648256	Disposed		Common Stock (303917)	Direct

Footnotes

F1: The Series D and Series E Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D and Series E Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: Robert Adelman and Corey Goodman, the managing partners of venBio Global Strategic Fund II LP ("venBio"), share voting and dispositive control over the shares held by venBio.